We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type

By LabMedica International staff writers
Posted on 10 Apr 2025

Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor. More...

A global grading system developed by the International Association for the Study of Lung Cancer (IASLC) links these growth patterns to the likelihood of disease progression or recurrence. However, the presence of multiple pattern types within a tumor and the variation in how each pattern appears across different tumors complicates the task of determining a patient's prognosis. This complexity, coupled with the challenge of defining and quantifying these growth patterns, often leads to discrepancies in tumor grading among pathologists. As a result, inconsistent or suboptimal grading could result in patients receiving inadequate or inappropriate treatment, which might compromise their outcomes. Although previous studies have explored the use of deep learning models for classifying growth patterns in lung adenocarcinoma, these models have typically not considered the detailed morphological structure of the patterns, nor have they been capable of performing automated IASLC grading.

In response to this challenge, researchers at the Institute of Cancer Research (ICR, London, UK) have developed an artificial intelligence (AI)-based model designed to help pathologists grade lung cancer tumors and predict patient outcomes by analyzing tumor growth patterns, which can vary greatly among individuals. In a recent study, the ICR team demonstrated that the model, named ANORAK (pyrAmid pooliNg crOss stReam Attention networK), was able to predict disease-free survival (DFS), a critical measure of the length of time between treatment for lung adenocarcinoma and the return of symptoms or signs of the disease. In the long term, the model could assist clinicians in determining the most effective treatment strategies based on the predicted progression of cancer. This improved decision-making could ultimately lead to better patient outcomes, especially in light of recent advancements in cancer screening programs that have led to more early-stage lung cancer diagnoses, underscoring the need for enhanced treatment decisions. The research, conducted by ICR scientists, was published in Nature Cancer.

In this study, the researchers used ANORAK to assess six types of lung adenocarcinoma growth patterns at the pixel level. They applied the model to 5,540 tumor samples from diagnostic slides, which came from 1,372 patients with the disease. The model proved effective in enhancing patient risk stratification, showing that those with IASLC grade 1 or 2 tumors had significantly longer DFS than those with grade 3 tumors. To validate the AI grading, the researchers compared it to manual grading results from three pathologists. They found that ANORAK’s grading was consistent with the pathologists' assessments, even slightly outperforming them for one cohort of patients. By referencing previous studies, the team confirmed that the agreement between AI and manual grading on the predominant growth pattern of a tumor was comparable to the level of agreement typically seen between different pathologists.

The study concluded that AI grading adds significant prognostic value, especially in early-stage lung adenocarcinoma, where treatment decisions are often challenging. In the second phase of the study, the researchers examined four specific scenarios that are typically difficult for pathologists, including cases with multiple diagnostic slides per tumor and those with highly diversified growth patterns. ANORAK performed well in all four scenarios, demonstrating its potential to assist pathologists even in complex cases. Additionally, the researchers focused on the acinar pattern, the most common of the six growth patterns, using ANORAK to better understand its structures and shapes. They also identified correlations between different acinar subtypes and tumor characteristics, some of which were associated with poorer prognoses. Moving forward, the researchers plan to incorporate genetic data into their model to gain deeper insights into tumor progression and the influence of surrounding cells and tissues. The team also intends to test ANORAK on larger groups of early-stage lung adenocarcinoma patients to gather more evidence of its effectiveness.

“Diagnostic inaccuracies and variability among pathologists are longstanding issues in lung adenocarcinoma. Our study is the first to implement the IASLC grading system with an AI-powered tool and validate the prognostic values on two distinct cohorts,” said Dr. Xiaoxi Pan, then a Postdoctoral Training Fellow in ICR’s Computational Pathology and Integrative Genomics Group and first author. “Our AI method enables the precise and automated quantification of unique growth patterns within a tumor, thereby inferring the predominant pattern and grading. It has also identified previously undiscovered morphological and spatial features of certain tissues that were not achievable using existing algorithms or human observations.”

Related Links:
ICR


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
New
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.